Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Immunology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Transplant Rejection Clinical Trials

A listing of Transplant Rejection medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (63) clinical trials

The goal of the OPTIMAL study is to gradually reduce anti-rejection medication(s) in liver transplant recipients over a period of time until the medication(s) are stopped. This is called immunosuppression withdrawal. As part of the OPTIMAL study, investigators will also do blood and liver biopsy tests to see whether they ...

Phase N/A

INTERCOMEX Donor-Derived Cell Free DNA Study

There is a need for better screening of kidney transplant patients for rejection. Patients with kidney transplants are routinely tested (creatinine, urine protein, histology and donor specific antibody (DSA) as standard of care to detect rejection, but these tests are not adequate. Rejection is often missed by these tests (false ...

Phase N/A

Assessment of Donor Derived Cell Free DNA and Utility in Lung Transplantation

Single Center Prospective Cohort Study on De-Novo Lung Transplant recipients. AlloSure will be drawn as part of routine blood draws and sent to CareDx for analysis of dd-cfDNA. All data will be collected and stored in the hospital EMR, this will be examined with the AlloSure results to correlate outcomes.

Phase N/A

Treatment of Chronic Active Antibody Mediated Rejection After Kidney Transplantation by Double-Filtration PlasmaPheresis or Plasma Exchange

Each year in the Renal Nephrology and Transplantation Department of Grenoble Hospital treat about twenty renal transplant patients with chronic active antibody rejection. Some patients are diagnosed at a very advanced stage and will not be treated because the expected benefit is tenuous (exclusion criteria). For both groups, patients will ...

Phase N/A

Cardiac MRI and Cardiac Allograft Rejection

Background Heart transplantation is a treatment for select patients with end-stage heart failure. Improvements in immunosuppressive therapies and patient management have increased the life expectancy of heart transplant patients. One-year survivals are 90% and 80%, with 65 % and 49% of pediatric and adult patients surviving 8 - 15 years ...

Phase N/A

The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)

The primary objective is to differentiate the clinical utility of Prospera testing from the use of creatinine testing as measured by the proportion of positive biopsies in post renal allograft patients. Secondary objectives include: To observe the performance of the Prospera assay in detecting AR (repeated validation) To evaluate whether ...

Phase N/A

Donor-Derived Cell-Free DNA for Surveillance in Simultaneous Pancreas and Kidney Transplant Recipients

This is a prospective and retrospective cohort study of recipients of simultaneous pancreas and kidney transplant recipients (SPK). New SPK transplant recipients and previous SPK transplant recipients from September 2012 will be enrolled in the study, expected duration of participation will therefore range from a minimum of 1 year to ...

Phase N/A

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

While patients surviving more than three years from SCT have a high probability of being cured of their underlying disease, they are still at risk from several categories of complications which could remain lifelong risks including late recurrence (or continued persistence) of original disease, late effects from transplant related GVHD, ...

Phase N/A

Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

The AlloSure test has been approved for Medicare coverage for clinical use when a physician determines there is a need to assess the probability of allograft rejection in kidney transplant recipients. The DART study suggests that use of the non-invasive AlloSure test to measure donor-derived cell-free DNA (dd-cfDNA) can be ...

Phase N/A

Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA

+Objective The objective of this prospective observational study is to correlate circulating dd-cfDNA to clinical and sub-clinical acute rejection in pancreas transplant alone (PTA), pancreas after kidney (PAK), and simultaneous pancreas kidney (SPK) allograft recipients. The secondary objective study is to correlate circulating dd-cfDNA to pancreas and kidney function, using ...

Phase N/A